Omics analyses in peritoneal metastasis—utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review

Lund-Andersen, Christin; Torgunrud, Annette; Fleten, Karianne G.; Flatmark, Kjersti

doi:10.21037/jgo-20-136

Cited by 17 publications

(15 citation statements)

References 62 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study found that in CRC cells, the expressions of PI3K, Akt, and mTOR were upregulated, indicating that the PI3K/Akt/mTOR pathway was activated, which is consistent with the aforementioned theory. Studies have shown that PIK3CA mutation can reduce the risk of CRC peritoneal metastasis ( Lund-Andersen et al, 2021 ). Mutated BRAF, PIK3CA, and PTEN have also been confirmed to exist in the EGFR signal transduction pathway.…”

Section: Discussionmentioning

confidence: 99%

Effects of GLP-1 Receptor Agonists on Biological Behavior of Colorectal Cancer Cells by Regulating PI3K/AKT/mTOR Signaling Pathway

Tong

Peng²,

Chen³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Colorectal cancer (CRC) has become one of the top ten malignant tumors with a high incidence rate and mortality. Due to the lack of a good CRC screening program, most of the CRC patients are being transferred at the time of treatment. The conventional treatment cannot effectively improve the prognosis of CRC patients, and the target drugs can significantly prolong the overall survival of patients in the advanced stage. However, the use of single drug may lead to acquired drug resistance and various serious complications. Therefore, combined targeted drug therapy is the main alternative treatment with poor effect of single targeted drug therapy, which has important research significance for the treatment of CRC. Therefore, this study intends to culture CRC cell lines in vitro at the cell level and intervene with the GLP-1 receptor agonist liraglutide. The effects of liraglutide on the PI3K/Akt/mTOR signal pathway and CRC cell proliferation, cycle, migration, invasion, and apoptosis are explored by detecting cell proliferation, cycle, migration, invasion, and apoptosis and the expression of related mRNA and protein. The results showed that liraglutide, a GLP-1 receptor agonist, could block the CRC cell cycle, reduce cell proliferation, migration, and invasion and promote apoptosis by inhibiting the PI3K/Akt/mTOR signal pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of GLP-1 Receptor Agonists on Biological Behavior of Colorectal Cancer Cells by Regulating PI3K/AKT/mTOR Signaling Pathway

Tong

Peng²,

Chen³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Consequently, molecular understanding of PMPs is shallow compared to other tumors, mostly limited to broad genetic and transcriptomic characterization. Genomic information points to known oncogenes and tumor suppressor genes KRAS, GNAS, TAT4, TGFBR1, TP53 and SMAD3/4 as the most frequently mutated in PMP, commonly linked to bad prognosis [5]. 5 At the transcriptional level, mucin related genes MUC-5AC, MUC-2, and TFF1/2 have been found overexpressed, while protein levels of TOPO1, TS and ERCC1 have been proposed as biomarkers in IHC studies.…”

Section: Discussionmentioning

confidence: 99%

“…HNRNPK is not the most commonly altered splicing factor in cancer, but various studies have previously found dysfunctions of in other tumors [24], including pancreatic adenocarcinoma [25], where its alteration is linked to activation of RAS family members, such as KRAS, a gene that, interestingly, is also found altered in PMP [5]. Likewise, several studies have addressed the role of PTBP1 in cancer, whereas its interacting co-factor RAVER1 is less known.…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, few studies have provided a more detailed analysis of PMP features, particularly their molecular pro le, and only on limited cohorts of patients, yielding ambiguous results that preclude to extract strong, generalizable conclusions. Thus, multiple mutations, such as in KRAS, GNAS, FAT4, TGFBR1, TP53 and SMAD3/4, have been reported in PMP, which are rather similar to those found in colorectal metastasis [5]. Likewise, few studies have assessed the putative impact of PMP molecular features on patient survival.…”

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

A New Molecular (P)Layer in Pseudomyxoma Peritonei: The Splicing Machinery is Dysregulated and Linked to Low Survival

Moreno-Montilla

Alors‐Perez

Martínez-López³

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose: Pseudomyxoma peritonei (PMP) is a rare cancer that causes chronic and uncontrollable mucus accumulation, gradually leading to intraperitoneal organ adhesion, bowel obstruction, malnutrition, and eventually cachexia and death. Aggressive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy offer the best results; but the probability of relapse remains high. The study of the distinct molecular layers underlying PMP is essential to understand its genesis and progression. Alternative splicing is emerging as a new player in all cancers, but its role in PMP is unknown. The aim of this work was to assess the splicing machinery status in PMP and determine its potential contribution to disease prognosis. Methods: A set of 62 splicing-related genes were evaluated in a cohort of 29 patients using a microfluidic array, and their levels were compared between tumor and non-tumor tissue and correlated to relevant clinical parameters. Selected components were validated by immunohistochemistry and subsequently studied in detail by enrichment analyses. Results: Results revealed a profound dysregulation of the splicing machinery at RNA/protein level, which allowed to distinguish between tumor and control tissues. Particularly, the splicing factors HNRNPK, MBNL1, PTBP1 and RAVER1were associated with poor prognosis and their expression was linked to TP53regulation and inflammation processes. Conclusions: These findings provide the first evidence for the dysregulation of the splicing machinery in PMP, suggesting that it could be functionally altered and play a role in this rare malignant disease. Therefore, its detailed understanding could help to identify novel prognostic biomarkers and therapeutic targets in PMP.

show abstract

“…However, symptoms of increased abdominal girth, intestinal obstruction and malnutrition can call attention to the accumulation of large amounts of mucinous tumor [1][2][3]. When the appendix ruptures, tumor cells spread throughout the abdominal cavity via paths of fluid re-absorption [4]. Sugarbaker's cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is considered the current standard of treatment [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Serum and ascites tumor markers in the diagnostic and prognostic prediction for appendiceal pseudomyxoma peritonei

Wang

Rao

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Background To investigate the expression of carcinoembryonic antigen (CEA), cancer antigen 199 (CA199) and CA125 in serum and ascites of appendiceal pseudomyxoma peritonei (PMP) patients relative to their diagnostic and predictive value. Methods The study comprised 183 patients with pathologically confirmed appendiceal PMP, enrolled from May 2012 to June 2020, in Aerospace Center Hospital. Serum and ascites tumor markers were obtained, and their diagnostic values were compared by receiver operating characteristic (ROC) curves. The prognostic factors of appendiceal PMP with different pathologic subgroups were calculated by univariate and multivariate Cox proportional hazard regression models. Results There were significant differences between the numbers of patients with positive CEA and CA199 in serum vs. ascites: p = 0.034 in CEA and p = 0.006 in CA199, respectively. The sensitivities with optimal cut-off values for ascites markers of CEA, CA199 and CA125 were 83.5%, 88.9% and 72.6%, respectively. CEA in ascites showed significant difference in the diagnosis of appendiceal PMP (p = 0.000); the areas under the ROC curves (AUROCs) and specificity were 0.725, 70.7%, respectively. Univariate analysis showed that the higher the ascites tumor markers, the poorer the survival (p = 0.014). Multivariate analysis indicated that completeness of cytoreduction (CCR), ascites CEA and pathological grade were independent risk factors for overall survival (OS). Conclusion CEA in ascites can be used to help specify the origin of PMP. Furthermore, elevation of ascites CEA, high pathological grade and incomplete cytoreduction predicted poor prognosis of appendiceal PMP.

show abstract

Omics analyses in peritoneal metastasis—utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review

Cited by 17 publications

References 62 publications

Effects of GLP-1 Receptor Agonists on Biological Behavior of Colorectal Cancer Cells by Regulating PI3K/AKT/mTOR Signaling Pathway

Effects of GLP-1 Receptor Agonists on Biological Behavior of Colorectal Cancer Cells by Regulating PI3K/AKT/mTOR Signaling Pathway

A New Molecular (P)Layer in Pseudomyxoma Peritonei: The Splicing Machinery is Dysregulated and Linked to Low Survival

Serum and ascites tumor markers in the diagnostic and prognostic prediction for appendiceal pseudomyxoma peritonei

Contact Info

Product

Resources

About